BR0307421A - Estimulação do cpt-1 como um freio para reduzir peso - Google Patents

Estimulação do cpt-1 como um freio para reduzir peso

Info

Publication number
BR0307421A
BR0307421A BR0307421-8A BR0307421A BR0307421A BR 0307421 A BR0307421 A BR 0307421A BR 0307421 A BR0307421 A BR 0307421A BR 0307421 A BR0307421 A BR 0307421A
Authority
BR
Brazil
Prior art keywords
cpt
agent
administered
fatty acid
amount sufficient
Prior art date
Application number
BR0307421-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Jagan N Thupari
Leslie E Landree
Gabriele Ronnett
Francis P Kuhajda
Original Assignee
Johns Kophkins University Scho
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Kophkins University Scho filed Critical Johns Kophkins University Scho
Publication of BR0307421A publication Critical patent/BR0307421A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Pediatric Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR0307421-8A 2002-02-08 2003-02-10 Estimulação do cpt-1 como um freio para reduzir peso BR0307421A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35448002P 2002-02-08 2002-02-08
PCT/US2003/003839 WO2003066043A1 (en) 2002-02-08 2003-02-10 Stimulation of cpt-1 as a means to reduce weight

Publications (1)

Publication Number Publication Date
BR0307421A true BR0307421A (pt) 2004-12-28

Family

ID=27734382

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307421-8A BR0307421A (pt) 2002-02-08 2003-02-10 Estimulação do cpt-1 como um freio para reduzir peso

Country Status (12)

Country Link
US (4) US20050143467A1 (https=)
EP (1) EP1471906A4 (https=)
JP (2) JP2005523270A (https=)
KR (1) KR20040082417A (https=)
CN (1) CN1313089C (https=)
AU (2) AU2003215111A1 (https=)
BR (1) BR0307421A (https=)
CA (1) CA2474884A1 (https=)
EA (1) EA007029B1 (https=)
IL (1) IL163312A (https=)
MX (1) MXPA04007556A (https=)
WO (1) WO2003066043A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2474884A1 (en) * 2002-02-08 2003-08-14 John Hopkins University School Of Medicine Stimulation of cpt-1 as a means to reduce weight
EA013371B1 (ru) * 2002-07-09 2010-04-30 Фасджен, Ллс. Новые соединения, содержащие их фармацевтические композиции и способы их применения
WO2005089773A1 (en) * 2004-03-18 2005-09-29 Fasgen, Llc Control of feeding behavior by changing neuronal energy balance
MXPA06013687A (es) * 2004-05-26 2007-10-18 Fasgen Llc Compuestos novedosos, composiciones farmaceuticas que los contienen y metodos para utilizar los mismos.
BRPI0610877A2 (pt) * 2005-06-06 2010-08-03 Hoffmann La Roche compostos, processo para a manufatura dos compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de l-cpt1 e utilização dos mesmos
WO2007014248A2 (en) * 2005-07-26 2007-02-01 Johns Hopkins University Method of reducing food intake
ATE418603T1 (de) * 2005-08-29 2009-01-15 Hoffmann La Roche Kristallstrukturen von carnitine palmitoyltransferase-2 (cpt-2) und deren verwendung
ES2405259B1 (es) * 2011-11-25 2014-09-29 Centro De Investigación Biomédica En Red Fisiopatología De La Obesidad Y Nutrición (Ciberobn) Uso del enantiómero (+)-c75 para el tratamiento de la obesidad.
WO2013155528A2 (en) * 2012-04-13 2013-10-17 Fasgen, Inc. Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574639A (en) 1897-01-05 Gold-saving device
DE3026368A1 (de) * 1980-07-11 1982-02-18 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion
US5981575A (en) 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
US5914326A (en) * 1997-08-08 1999-06-22 Ambi Inc. Method for promoting weight and fat loss
US6413545B1 (en) * 1998-09-01 2002-07-02 Access Business Group International Llc Diet composition and method of weight management
KR20090031957A (ko) * 1999-11-12 2009-03-30 더 존스 홉킨스 유니버시티 세포내 말로닐 ＣｏＡ의 수준을 증가시킴에 의한 암의 치료방법
WO2001060174A2 (en) * 2000-02-16 2001-08-23 The Johns Hopkins University School Of Medicine Weight loss induced by reduction in neuropeptide y level
WO2002079501A1 (en) * 2001-03-30 2002-10-10 Trustees Of Boston University Methods and reagents for identifying weight loss promoters and therapeutic uses therefor
CA2474884A1 (en) * 2002-02-08 2003-08-14 John Hopkins University School Of Medicine Stimulation of cpt-1 as a means to reduce weight
US20040161803A1 (en) * 2002-04-01 2004-08-19 Corkey Barbara E. Methods and reagents for identifying weight loss promoters and therpeutic uses therefor
US20060241177A1 (en) 2002-07-01 2006-10-26 Kuhadja Francis P Novel compounds, pharmaceutical compositions containing same, and methods of use for same
EA013371B1 (ru) 2002-07-09 2010-04-30 Фасджен, Ллс. Новые соединения, содержащие их фармацевтические композиции и способы их применения

Also Published As

Publication number Publication date
US20050143467A1 (en) 2005-06-30
EP1471906A1 (en) 2004-11-03
CA2474884A1 (en) 2003-08-14
US20070087037A1 (en) 2007-04-19
US20050106217A1 (en) 2005-05-19
IL163312A (en) 2011-12-29
CN1638758A (zh) 2005-07-13
US7459481B2 (en) 2008-12-02
US20090124684A1 (en) 2009-05-14
JP2010047594A (ja) 2010-03-04
KR20040082417A (ko) 2004-09-24
WO2003066043A1 (en) 2003-08-14
AU2008249144A1 (en) 2008-12-11
EA200401052A1 (ru) 2005-02-24
EP1471906A4 (en) 2006-02-01
EA007029B1 (ru) 2006-06-30
CN1313089C (zh) 2007-05-02
MXPA04007556A (es) 2005-12-05
JP2005523270A (ja) 2005-08-04
AU2003215111A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
Bianchi et al. Endocrine aspects of Duchenne muscular dystrophy
Liu et al. The effect of the modified eighth section of eight-section brocade on osteoporosis in postmenopausal women: a prospective randomized trial
FI920026A0 (fi) Farmaceutisk komposition anvaendbar som avmagringsmedicin.
DK1423062T3 (da) Revaliderende indlægssålanordning
Wilson et al. Effect of skeletal muscle fiber type on the pressor response evoked by static contraction in rabbits
BR112022004587A2 (pt) Métodos para tratar narcolepsia tipo 1, diminuir eventos tipo cataplexia, aumentar concentração de cálcio intracelular, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, tratar uma doença associada a nível de orexina reduzido, aumentar alerta, melhorar classificação de escala de sonolência epworth, e, composição farmacêutica
EA200701131A1 (ru) Гелеобразная препаративная форма капсаициноида и способы её применения
MX9400060A (es) Derivados ester del hexahidronaftaleno, su preparacion y sus usos terapeuticos.
Yuan et al. Application and progress of blood flow restriction training in improving muscle mass and strength in the elderly
BR9911020A (pt) Novas composições farmacêuticas para tratamento e salvamento, e método para a sua preparação
BR0307421A (pt) Estimulação do cpt-1 como um freio para reduzir peso
JP2004532215A (ja) 睡眠時の自律的安定性に関するカンナビノイドの機能的役割
Karpov et al. Possibilities of regular physical culture lessons in restoring the functional status of students
Liu et al. Overview of physical and pharmacological therapy in enhancing bone regeneration formation during distraction osteogenesis
CA2761458C (en) Fragrance composition having good sleep-inducing effect
JP2021526947A (ja) 美容、脳卒中、特発性顔面神経麻痺患者が顔の骨および筋肉を鍛えるための装置および使用方法
Starnes et al. Synergistic effect of exercise and statins on femoral strength in rats
Mansouri et al. Malondialdehyde and Lipid Peroxidation
BRPI0519016A2 (pt) agente preventivo ou terapÊutico para distérbios do sono, uso de uma droga, e, mÉtodo para prevenÇço e/ou tratamento de distérbios do sono
Calvani et al. Bone level technique: personal technique for miofacial functional treatment
RU2302256C1 (ru) Ароматическая композиция, нормализующая психоэмоциональное состояние (варианты)
Ilona et al. The role of high-impacts exercises in improve bone mineral density in postmenopausal women with osteopenia or osteoporosis
Krivoshchekov et al. Individual characteristics of external respiration during intermittent normobaric hypoxia
Tayebi et al. Effects of resistance training on performance and physiological indices in patients with ischemic stroke: a systematic review and meta-analysis
DE502005001398D1 (de) Hautpflegeprodukt enthaltend Ursolsäure und Ginkgo-Extrakt

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/195, 31/198, 31/205, 31/34, 31/381, 45/00; A61P 3/04, 43/00; G01N 33/15, 33/50

Ipc: A61K 31/195 (2011.01), A61K 31/198 (2011.01), A61K

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 9A ANUIDADE.